Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.
Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores
Lindfors NC
Bioactive glass (BAG) S53P4 is a bone bonding, osteoconductive and osteostimulative bone substitute with proven antibac-terial properties. In this paper, several clinical aspects using BAG S53P4 in reconstructive surgery in the upper extremity is presented, demonstrating bone remodelling, vascularization, cartilage repair and antibacterial properties of BAG S53P4. In a prospective, randomized, long-term study, BAG S53P4 was compared to autograft bone, in nine patients, in treatment of benign bone tumours in the hand. No radiological difference between the two groups was observed at 18 months. No material-related adverse effects were observed at the 14-year long-term follow-up. In the BAG group, a thickened cortex was observed on CT. MRI revealed that the bone marrow was mainly or partly fatty. BAG S53P4 was used in treatment of an intra-articular condylar open fracture in a child. In a re-operation, it was observed that the treated region was vascularized at three months, which was histopathologically confirmed. The vascularized bone substitute mass had supported the injured cartilage. An angulation of the proximal interphalangeal joint was observed but this did not affect the use of the hand. The finger was painless and stable. Finally, BAG S53P4 was used in treatment of an infected comminuted olecranon fracture. The patient had sustained a fistular formation to a previously used bone substitute. The pathogen causing the infection was S epidermidis. In a re-operation BAG S53P4 was used as bone substitute. No re-infection was observed during a six-month follow-up.